All News
JAMA Review of DMARD Use in Rheumatoid Arthritis
JAMA has reviewed the "2022 EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs".
Read Article
Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women
A follow-up analysis of a randomized clinical trial found that the use of calcium and vitamin D supplements among postmenopausal women was associated with decreased risk for cancer mortality, but increased risk for cardiovascular disease (CVD) mortality.
Read Article
JAK inhibitors maybe an option in refractory Juvenile Dermatomyositis. Metanalysis of 26 reports (195 pts) JDM Rx w/ JAKi (median 5 rys); most Rx w/ tofacitinib (57%), ruxolitinib(27%), baricitinib (15%), w/ Improvement in 90%, 69%, 93%, respectively. https://t.co/acdlU13MfX https://t.co/fTFVvPz0EH
Dr. John Cush RheumNow ( View Tweet)
Lyme Disease 2022
The CDC has updated its Lyme disease surveillance report based on a new case definition. Compared to 2017–2019, the number of cases in 2022 rose by 69%.
https://t.co/iCAbSYbhsB https://t.co/7q8hCXV1CZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Increased Depression on Rheumatoid Arthritis
A Korean nationwide cohort study found that both seropositive and seronegative rheumatoid arthritis (RA) patients have a significantly higher risk of depression.
https://t.co/9AtlBrDTUJ https://t.co/vKEhBfkHQD
Dr. John Cush RheumNow ( View Tweet)
Greek study of 160 #GCA pts (age 72 yrs) - all on Hi dose steroids (GC) @ start, 37% DMARD & 16% biologic. @ 2 Yrs, 42% D/C GC & 27% had Relapses. Predictors of relapse = LG vessel involv (OR=4.2), CV event (4.6) & higher initial GC doses (OR=1.04) https://t.co/FshaslTuSI https://t.co/y9uVgkR58Y
Dr. John Cush RheumNow ( View Tweet)
Starting MTX at higher or subcut. doses yields better ACR20 responses. Review of 12 trials & 1,566 pts, shows:
- higher initial MTX 25 mg (but more GI AEs)
- SC MTX more ACR20 resp (85% vs PO 77%)
- MTX non-response, success w/ SC MTX
https://t.co/01PuDpkUIF https://t.co/vXLWEp4srH
Dr. John Cush RheumNow ( View Tweet)
Japanese study of 96 #SLE pregnancies: 59 in remission @ conception. Remission had fewer adverse preg outcomes (OR 0.27) vs those w/ activity. No difference in APO based on serologies, but Pred ≥7.5/d us had signif. more APO. (OR 3) https://t.co/BvOeiSERN9 https://t.co/ePh1dqdJvS
Dr. John Cush RheumNow ( View Tweet)
Polyarteritis Nodosa (PAN): Clinical Features and Outcomes
A multinational study of PAN through the international GLOBAL-PAN network shows PAN to be a complex, multisystem disorder with a high risk of relapse and low risk of death (11% at 10 years).
https://t.co/cyCzxRnjJf https://t.co/DleD9cYFTb
Dr. John Cush RheumNow ( View Tweet)
Frensius-Kabi has announced that the FDA has approved the tocilizumab biosimilar, Tyenne (tocilizumab-aazg); the first TCZ biosimilar with both IV and subcutaneous formulations https://t.co/F3d8DKxpkU https://t.co/NSEqAcoBBo
Dr. John Cush RheumNow ( View Tweet)
Review article on inclusion body myositis, a progressive, debilitating myopathy w/ onset > 50 yrs. IBM typically has asmmetric, painless, weakness & atrophy of finger flexors or quadriceps w/ dysphagia. Most are wheelchair bound w/in 13-15 years https://t.co/LoWtmDqimu https://t.co/N3OUU7QMc1
Dr. John Cush RheumNow ( View Tweet)
The more you know, the more you realize how much you don’t know. The less you know, the more you think you know everything. Knowledge is humbling. Ignorance is arrogant.
Prof. Feynman ProfFeynman ( View Tweet)
Can Mycophenolate be Stopped in Stable SLE?
https://t.co/8oQx0cqDr3 https://t.co/mlt2Qqj8wm
Dr. John Cush RheumNow ( View Tweet)
COVIDs Extended Risk for Rheumatic Disease
Annals of Internal Medicine reports a large, binational study finding SARS-CoV-2 infection was associated with an increased risk for AIRDs that extends up to 12 months after infection.
https://t.co/HjQ56hiiny https://t.co/vvC3iVqNyF
Dr. John Cush RheumNow ( View Tweet)
Review of autoimmune Dz & adverse preg outcomes: Incr risk of:
- Miscarriage w/ Sjögrens (RR 8.85) & SLE (OR 4.9)
- Preeclampsia w/ SLE (OR 3.2)
- IUGR w/ scleroderma (OR 3.2) & celiac (OR 1.71)
- Preterm birth w/ SLE (OR 2.79).
https://t.co/bll2x2aS9Z https://t.co/Eg0sVBcPmR
Dr. John Cush RheumNow ( View Tweet)
Sandoz has announced FDA approval for their two interchangeable biosimilars of denosumab - Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) based on reference products Xgeva and Prolia https://t.co/Spb0ABOMMm https://t.co/wkMurvB0G3
Dr. John Cush RheumNow ( View Tweet)
Lancet - Full Read Review of the Diagnosis and management of ANCA-associated vasculitis
by Stone, et al https://t.co/Lg0FKR8RZ4 https://t.co/RUpK00YmTh
Dr. John Cush RheumNow ( View Tweet)
Machine learning of 701 Anti-Synthetase (Anti-Jo1, -PL7, -PL12, -EJ) identifies 3 Endotypes,independent Ab specificity
#1 (24%) w/ RP-ILD & high mortality
#2 (14%) dermatomyositis, intermediate prognosis
#3 (62%) arthritis & mechanics hands, good prognosis https://t.co/4NqZp4yR18 https://t.co/rBrhBxxniR
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Community-Acquired Pneumonia (CAP)
https://t.co/AMConIb14r https://t.co/BCfcHc5i37
Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/a3XeAa2lcG https://t.co/dTZa2uQF97
Dr. John Cush RheumNow ( View Tweet)